Navigation Links
Light Sciences Oncology Expands Development of Novel Targeted Drug Aptocine(TM) For Prostate Conditions With Start-Up of Phase 2 BPH Trial
Date:8/18/2009

BELLEVUE, Wash., Aug. 18 /PRNewswire/ -- Light Sciences Oncology, Inc. (LSO) today announced the treatment of the first patients in a Phase 2 clinical trial of its innovative targeted drug treatment Aptocine(TM) (talaporfin sodium) in Benign Prostatic Hyperplasia (BPH). The Phase 2 trial expands the Aptocine BPH development program on the basis of a Phase 1 study at escalating light doses. In the open-label Phase 2 trial, Aptocine is being tested for safety and efficacy in 40 patients with lower urinary tract symptoms (LUTS) due to BPH. Aptocine is also in two Phase 3 clinical trials for solid tumors in the liver as well as preclinical development for prostate cancer.

"Beyond Aptocine's late-stage development as a revolutionary treatment for solid tumors, we believe Aptocine also presents a new paradigm in treating benign neoplasms such as BPH," said LSO's President and CEO, Llew Keltner, M.D., Ph.D. "The Phase 2 BPH trial greatly widens the potential of Aptocine as a uniquely safe and effective targeted therapy."

Benign prostatic hyperplasia (BPH) is a nonmalignant enlargement of the prostate. The most common clinical manifestation of BPH is lower urinary tract symptoms, including urinary frequency, urgency, nocturia, decreased and intermittent force of urine stream and sensation of incomplete bladder emptying. BPH is a disease of the aging male population with a dramatic increase in incidence after the age of 50 years. The American Urological Association estimates that BPH will affect approximately 50 percent of men between the ages of 51 and 60 and up to 90 percent of men over the age of 80.

The primary outcome measures of the Aptocine Phase 2 BPH trial are safety, according to number and severity of adverse events, and preliminary effectiveness, according to evaluation using the International Prostate Symptom Score (IPSS) and Bother Score (BS). Complete information on study protocol, investigators, and sites is available at ClinicalTrials.gov with the identifier: NCT00918034 (http://clinicaltrials.gov/ct2/show/NCT00918034).

About Aptocine

Aptocine is a water-soluble drug targeted inside a tumor or other tissue by a small, single-use, disposable drug activator included with the drug. The drug activator contains a tiny array of LEDs that emits red light at a discrete frequency and intensity, for a fixed time period, to activate Aptocine and create a "treatment region" around the LED array. Constant illumination with the LEDs' low-intensity light can activate each molecule of Aptocine many times, resulting in a continuous supply of singlet oxygen molecules that can kill target tissues with minimal side effects through vascular closure and apoptosis. The Aptocine drug activator used in BPH is a linear LED array inside a standard catheter, providing a simple, easy-to-administer outpatient treatment. Administering physicians insert the catheter with LED array into the urethra, inject Aptocine intravenously, and then energize the drug activator. Aptocine advantages over existing therapies for BPH may include minimal side effects, safety, and repeatability.

About Light Sciences Oncology

Light Sciences Oncology (LSO) is developing Aptocine for solid tumors as well as benign neoplasms such as BPH. LSO has completed treatment of patients in a Phase 3 trial of Aptocine in hepatocellular carcinoma (HCC) and is currently enrolling patients in a Phase 3 trial for metastatic colorectal cancer (MCRC). LSO is also conducting clinical trials of Aptocine in patients with BPH and in neurofibromatosis, and has clinical or preclinical programs in cardiovascular disease, eye disease, and dermatology.

    Contacts
    Light Sciences Oncology, Inc.
    Llew Keltner, M.D., Ph.D.
    President & CEO
    425-957-8940
    dr_llew@lsoncology.com

    Robert M. Littauer
    Vice President,
    Chief Financial Officer
    & Treasurer
    425-957-8946
    bobl@lsoncology.com

www.lsoncology.com

Aptocine(TM) is a trademark of Light Sciences Oncology, Inc.


'/>"/>
SOURCE Light Sciences Oncology, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. EF Johnson Technologies, Inc. Highlights New Products at APCO 2009
2. August 2009 Mayo Clinic Womens HealthSource Highlights Health Care Dollars, Senses of Taste and Smell, and Emotional Eating
3. August 2009 Mayo Clinic Health Letter Highlights Herbal Supplements, Groin Rashes and Hand Arthritis
4. Lee County Schools "Lightens Up" by 2000 lbs and saves big
5. DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results
6. Lumie Reveals Light Levels Received In July Are As Low As A Winter's Day
7. Sunlight May Cause Rash in Autoimmune Disease
8. DUSA Pharmaceuticals, Inc.(R) Announces Second Quarter Financial Results and Corporate Highlights Conference Call
9. 11th Annual Light the Night Date Announced
10. Class Action Notice for Minnesota Light Cigarette Litigation From Lommen, Abdo, Cole, King & Stageberg, P.A.
11. Smith & Nephew Highlights Advanced Wound Management Progress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... , ... June 26, 2016 , ... PawPaws brand ... new product that was developed to enhance the health of felines. The formula is ... The two main herbs in the PawPaws Cat Kidney Support Supplement Soft ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the ... several important health care topics including advance care planning, healthcare costs and patient ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... "With 30 ... their specific project," said Christina Austin - CEO of Pixel Film Studios. , ... and all within Final Cut Pro X . Simply select a ProHand generator ...
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... people are unfamiliar with. The article goes on to state that individuals are now ... of these less common operations such as calf and cheek reduction. The Los Angeles ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Bracket , a leading clinical trial technology ... outcomes platform, Bracket eCOA (SM) 6.0, at the 52 ... 30, 2016 in Philadelphia , Pennsylvania.  A ... product of its kind to fully integrate with RTSM, will ... 6.0 is a flexible platform for electronic clinical outcomes assessments ...
(Date:6/23/2016)... PARK RIDGE, Ill. and INDIANAPOLIS ... caliber of students receiving a Lilly Diabetes Tomorrow,s Leaders ... hands. The 2016 scholarship winners, announced today online at ... refused to let type 1 diabetes stand in the ... Lilly Diabetes has supported the Foundation,s scholarship program since ...
(Date:6/23/2016)... -- Revolutionary technology includes multi-speaker listening to ... leaders in advanced audiology and hearing aid technology, has ... the world,s first internet connected hearing aid that opens ...      (Photo: http://photos.prnewswire.com/prnh/20160622/382240 ) , ... firsts,: , TwinLink™ - the first dual ...
Breaking Medicine Technology: